Tianfeng Securities: Initiates "Buy" rating for KHPG with a target price of 51.84 yuanZhitong·Oct 14, 2025 at 01:36 AM002773+0.37%
KHPG: Ipasitide tablets have obtained a drug registration certificateZhitong·Sep 28, 2025 at 11:06 PM002773+0.37%
KHPG: Criminals are using the company's name to carry out fraud and other activitiesZhitong·Aug 12, 2025 at 08:53 AM002773+0.37%
The concept of innovative drugs has strengthened again, with Hotgen rising over 10% to reach a new historical highZhitong·Aug 5, 2025 at 08:39 PM002773+0.37%688068+4.55%
KHPG: Currently, production and business activities are normal, and there are no significant matters that should be disclosed but have not been disclosedZhitong·Jul 21, 2025 at 05:36 AM002773+0.37%
KHPG: Received the drug registration certificate for Lifi Shite eye dropsZhitong·Jun 30, 2025 at 06:21 AM002773+0.37%
The innovative drug concept surged and then fell back, with Sinovac Biotech dropping over 10%36Kr·Jun 16, 2025 at 09:52 PM688799+3.19%002773+0.37%
KHPG's subsidiary Songling Xuemai Kang capsules approved for clinical trialsZhitong·Jun 11, 2025 at 07:11 AM002773+0.37%
May 30th Midday Review: The ChiNext Index fell 0.88% in half a day, while the innovative drug concept surged against the trendWallstreetcn·May 29, 2025 at 10:31 PM601838-1.12%002082+4.92%
KHPG's subsidiary injectable KH617 has been approved to conduct clinical trialsZhitong·May 25, 2025 at 10:51 PM002773+0.37%
KHPG: Injectable KH815 has received approval for clinical trialsZhitong·Apr 16, 2025 at 06:34 AM002773+0.37%
